Prognostic Factors of Hilar Cholangiocarcinoma Patients After Surgical Resection

Gangshan Liu
Shengjing Hospital of China Medical University

Shuodong Wu
Shengjing Hospital of China Medical University

Jiannan Zhao
Shengjing Hospital of China Medical University

Xuecheng Li
Shengjing Hospital of China Medical University

Ying Fan (✉ m18940258876@163.com)
Shengjing Hospital of China Medical University

Research

Keywords: Surgical resection, Hilar Cholangiocarcinoma, Prognosis

DOI: https://doi.org/10.21203/rs.3.rs-25031/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

Hilar cholangiocarcinoma (HC) is one of the most common malignancies in China with poor prognosis and its incidence rate is increasing. Surgical resection is the most possible curative treatment option. However, comprehensive knowledge of prognostic markers is less or not accurate. So, the aim of this study was to analyze the prognostic factors in the surgical resection of HC patients.

Methods

A retrospective analysis of 85 cases of HC patients attending our hospital between January 2014 and December 2018 were included in the study. The patients diagnosed as HC and treated with radical surgery were included. Excluded the patients undergoing non-radical surgery, with tumors in other organs, with perioperative death, with death not caused by this disease and with lost follow-up. The clinical data were collected from the Hospital Information System. The patients was follow-up history at July 2019. The end point was that the patient died of recurrence of HC. Cox proportional hazards model analysis was performed to identify indexes of prognosis. All indicators were analyzed by univariate and multivariate analysis.

Results

The significantly related prognostic factors are imaging staging, blood loss during surgery, lymphatic metastasis, tumor size, Tumor Node Metastasis (TNM) stage, surgical margin and level of carbohydrate antigen 19–9 (CA19-9) in blood. Among them, TNM stage, surgical margin and level of CA19-9 in blood are independent prognostic factors.

Conclusions

Good prognosis in HC patients is indicated by early stages of TNM staging, no resection margin invaded and low level of CA19-9.

Background

Hilar cholangiocarcinoma (HC), firstly described by Klatskin, is a malignant tumor originated from bile duct epithelium with poor prognosis [1]. It is accounting for more than 60% of bile duct carcinoma, but only 2% of human malignant tumors [2]. It is also one of the most common cancers in China and its incidence rate is increasing [3]. Surgical resection is considered to be the most possible curative approach to offer patients opportunity for long-term survival [4]. However, although some patients undergo surgical resection, the recurrence rate in those patients is very high [5, 6]. There is a multitude of risk factors related to HC patients, such as aging, gender, primary sclerosing cholangitis, choledochocyst, bile duct stones, cholangitis, parasitic infection, inflammatory bowel disease and liver cirrhosis [7]. Also, researches show that tumor
differentiation, tumor staging, resection margin and lymph node metastasis are independent prognostic factors [8]. But there were not enough prognostic studies about height, weight, Body Mass Index (BMI), American Society of Anesthesiologists (ASA) grade, serum total bilirubin (TBIL), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartic aminotransferase (AST), albumin (ALB), CA19-9, operative time, biliary plastic or intraoperative blood loss. In addition, there is no accurate conclusion about the follow factors: removal of the caudate lobe, tumor size and intraoperative blood transfusion, et al [9, 10]. All of the aforementioned indices can thus maybe important indicators for further decision-making after surgery. Therefore, the aim of this study is to investigating the 22 prognostic factors of HC after surgical resection. By the way, we are aim to provide the data in resent five years of our hospital.

Methods

Patients

We retrospectively collected the clinical data of HC patients who underwent surgical treatment in Shengjing hospital of China Medical University between 2014 and 2018. The clinical data were collected from the Hospital Information System. The patients diagnosed as HC and treated with radical surgery were included. Excluded the patients undergoing non-radical surgery, with tumors in other organs, with perioperative death, with death not caused by this disease and with lost follow-up. The patients was follow-up at July 2019. The end point was that the patient died of recurrence of HC. A total of 120 consecutive patients diagnosed with HC and underwent surgery. Of the 120 patients, 85 had follow-up results available and were enrolled in this study.

Statistical analyses

All statistical analyses were performed using the SPSS statistical software package (SPSS Standard version 20.0). A P < 0.05 in a two-sided analysis was considered to be statistically significant. Cox single-factor analysis was used to include the correlated prognostic factors. Then according to the included factors, Cox proportional hazard model for multivariable regression analysis was used to determine the independent prognostic factors and present the Comprehensive test of model coefficients at the end.

Results

The 85 enrolled patients included 56 men and 29 women (average 63 years old) with age of onset of HC ranging between 45 and 84 years. The clinical pathological characteristics of the 85 patients are summarized in Table 1. Men were comparatively more predisposed to HC than females. There were 16 patients in ASA grade Ⅲ and 69 in grade Ⅱ. Ranges of operative time and estimated blood loss were 80 to 668 minutes and 50 to 2500 ml, respectively. For most of the people, many relevant biochemical examinations such as AST, ALT, ALP, TBIL and CA19-9 are higher than normal range. 50 patients needed blood transfusion in 85 patients. About 21 patients have Caudate lobe resection and the range of the tumor size was 0.5 cm to 6 cm. The mean diameter of the tumor was 2.676 cm as measured in the pathological report. Classified according to TMN stage, there were 23 in stage I, 31 in stage II, 26 in stage III, and 5 in stage IV.
Patients were followed up in January 15, 2019. We determined the relationship between observed indexes and postoperative prognosis using Cox single-factor regression analysis (Table 2). Seven indexes were significantly correlated (P<0.05): imaging staging, CA19-9, blood loss during surgery, lymphatic metastasis, TNM staging, tumor size and resection margin (Table 2).

All seven indexes were used in Cox model regression analysis. With α=0.05, we were able to import three independent factors related to HC postoperative prognosis because all variables passed the Cox multivariable analysis (Table 3). And the comprehensive test of the model coefficients can be seen in Table 4.

The risk of death increased by 1.794 times as TNM staging increases a level. The risk of death on patients with negative resection margins was 0.266 times that of patients with positive resection margins. Patients who had high CA19-9 in blood had a risk of death 2.602 times that of those who had normal CA19-9, and the patients who had high CA19-9 more than 1000 u/ml had a risk of death 2.602 times that of those who had high CA19-9 but less than 1000 u/ml.

Discussion

Survival of patients with HC is relatively poor. Surgery remains the only line of treatment offering the possibility of cure. But most HC patients are at an advanced, unresectable stage when diagnosed. The resectability rate of HC is different from 20 to 80% according to previous studies. Even in those who can receive radical resection, there is high risk of relapse. The actual 5-year survival after radical resection of HC varies widely from 14 to 48% [11–17]. We thus performed a single-factor analysis with the subsequent multi-factor analysis to determine the prognostic factors in the surgical resection of HC patients.

As summarized in Table 2, our analysis revealed 7 indexes that could affect prognosis in HC patients. Our study gets the result that height, weight, BMI, ASA grade, serum total bilirubin, ALP, ALT, AST, ALB, operative time, biliary plastic or resect Caudate lobe or not are not associated with the prognosis. It also has been previously shown that early stages of TNM staging was a significant good prognosis factor [18] and we get the same result. It is difficult to investigate the true effect of surgical resection and disease prognosis in the clinical because most cases are in advanced stage when diagnosed and do not receive surgical resection. So more people are needed to devote themselves to this field.

CA19-9 has been suggested as a prognostic marker for HC patients undergoing tumor resection [19] in 2014. But Sven H [20] suggested that carcinoembryonic antigen (CEA) but not CA19-9 was an independent prognostic factor in patients undergoing resection of cholangiocarcinoma in 2017. However, we got the conclusion that CA19-9 was an independent prognostic factor of HC patient after surgical in this study. So the prognostic values of CA19-9 in the clinical setting of surgical resection have remained inconclusive. We
hold the opinion that serum levels of CA19-9 are also elevated in patients with non-malignant biliary diseases such as primary sclerosing cholangitis or biliary obstruction due to choledocholithiasis[21, 22]. Therefore, further related articles are urgently needed.

Many reports indicate that a positive resection margin strongly affects prognosis. Hirano et al. [23] reported that the survival rates among patients with histologically positive margins were significantly inferior to the corresponding rates observed in patients with negative margins. The present study also revealed that proximal margin positivity (hazard ratio [HR], 2.688; p = 0.007) was independent survival prognostic factor[24]. We also got the result that positive margins was an independent prognostic factor. However, several authors have suggested that patients whose positive margins contain carcinoma could survive beyond 5 years. Volkan Öter et.al [25] reported that the survival of patients with tumor positive margins was not found to be worse than those with tumor negative margins. Further large volume prospective studies are required to identify the impact of positive proximal margins on the survival rate.

As we performed single-factor analysis, the statistical tests on imaging staging, lymphatic metastasis, tumor size have statistical -interpretation. But when doing multi-factor analysis, they do not have difference in statistical tests, which indicates they maybe not independent prognostic factors. But Hai-Jie Hu et.al [26] got the conclusion that Bismuth classification type III/IV was independent factors of overall survival in the subgroup of patients who developed early recurrence. Yunfeng Gao[27] reported that Patients with greater numbers of negative lymph nodes had an increased cancer-specific survival rate compared to patients with fewer negative lymph nodes. In the study of Felice Giuliante[28],the ratio of positive to negative lymph nodes was the only independent prognostic factor for overall survival but was influenced by the total number of retrieved lymph nodes.In this respect, thorough lymph nodes dissection may be important, and should be prospectively evaluated and studied in the future.

The limitations of this study mainly include the following: Only one follow-up was conducted, so it is only suitable for COX analysis, not for survival analysis. It is planned that in the future that further follow-up would be conducted for the survival of such patients until death or loss of follow-up. Some major indicators cannot be studied due to incomplete data, such as CEA, CA125 and postoperative complications.

Conclusions

In conclusion, our data seem to indicate that early stages of TNM staging, no resection margin invaded and low level of CA19-9 are good prognostic factors of HC. Though imaging staging,blood loss during surgery, lymphatic metastasis and tumor size are not independent factors in this study,they are significantly related to prognosis(p < 0.05) of HC.Patients with risk factors should be monitored closely after curative surgery.There are also many factors that were not studied in this article.Thus it is imperative to conduct further research to gain understanding and provide reference value for comprehensive treatment strategies for HC.

Abbreviations

HC
Hilar cholangiocarcinoma
CA19-9
carbohydrate antigen19–9
ALP
alkaline phosphatase
ALT
alanine aminotransferase
AST
aspartic aminotransferase
ALB
albumin
CEA
arcinoembryonic antigen
TBIL
total serum bilirubin
BMI
Body Mass Index
ASA
American society of anesthesiologists
TNM
Tumor Node Metastasis

Declarations

Ethics approval and consent to participate

This study was reviewed and approved by the Institutional Review Board of Shengjing hospital of China Medical University. Informed consent was obtained for all patients’ data.

Consent for publication

Written informed consent was obtained from all the patient for publication of this article.

Availability of data and materials

The data sets used and analyse during the study are available from the corresponding author and first author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding
Funding information is not applicable.

Authors' contributions

Gangshan Liu, Ying Fan, Jiannan Zhao, Xuecheng Li have been involved in the data collection of the patient. Gangshan Liu and Ying Fan have been involved in the Study designing and date analysis. All authors read and approved the final manuscript.

Acknowledgements

The first author acknowledges to all the authors and department leaders for their contributions and support.

References

1. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med, 1965, 38:241–56.

2. Bragazzi MC, C V, Carpino G, et al. Cholangiocarcinoma: Epidemiology and risk factors: A Retrospective Study of 293 Patients. Transl Gastrointest Cancer, 2012, 1:21–32.

3. Zhi-yuan Mao, Xiao-chuan Guo, Dan Su. et al. Prognosis in cholangiocarcinoma patients. Med Sci Monit, 2015; 21: 2375-2381.

4. Michael E. Lidsky, William R. Jamagin. Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center. Ann Gastroenterol Surg, 2018, 2:304–312.

5. Nault JC. Reports from the International Liver Cancer Association (ILCA) congress 2014. J Hepatol, 2015; 62(2): 477–82.

6. Salvador VB, Samroa P, Leytin A et al. Atypical presentation of an advanced obstructive biliary cancer without jaundice. Am J Case Rep, 2013; 14: 462–66.

7. Miguel Angel Suarez-Munoz, Jose Luis Fernandez-Aguilar, Belinda Sanchez-Perez, et al. Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol, 2013, 5(7): 132-138.

8. Hai-Jie Hu, Hui Mao, Anuj Shrestha, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol, 2016, 22(8): 2601-2610.

9. Norihisa Kimura, Yoshikazu Toyoki, Keinosuke Ishido, et al. Perioperative Blood Transfusion as a Poor Prognostic Factor After Aggressive Surgical Resection for Hilar Cholangiocarcinoma. J Gastrointest Surg, 2015; 19:866–879.

10. Annemiek M. Dekker, Jimme K. Wiggers, Robert J. Coelen, et al. Perioperative blood transfusion is not associated with overall survival or time to recurrence after resection of perihilar cholangiocarcinoma. HPB, 2016, 18:262–270.

11. Abd ElWahab M, El Nakeeb A, El Hanafy E, et al. Predictors of long-term survival after hepatic resection for hilar cholangiocarcinoma: a retrospective study of 5-year survivors. World J Gastrointest Surg, 2016; 8:436–43.
12. Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg, 2005;241:77–84.

13. Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. Am J Surg, 2008;196:160–9.

14. Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129–40.

15. Silva MA, Tekin K, Aytekin F, et al. Surgery for hilar cholangiocarcinoma: a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol, 2005;31:533–9.

16. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg;1999;230:808–18; discussion 819.

17. Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: the Nagoya experience. HPB Oxf. 2005;7:259–62.

18. Zhi-yuan Mao, Xiao-chuan Guo, Dan Su, et al. Prognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293 Patients. Med Sci Monit, 2015; 21: 2375-2381

19. Cai, W.-K. et al. Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int. J. Clin. Exp. Pathol. 2014;7, 7890–8.

20. Sven H. Loosen, Christoph Roderburg, Katja L. Kauertz, et al. CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of Cholangiocarcinoma. Scientific Reports, 2017; 7: 16975

21. Lin MS, Huang JX, Yu H. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int. J. Clin. Exp. Med. 2014;7, 744–50.

22. Ince, A. T. et al. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions. Turk. J. Gastroenterol. 2014; 25, 162–9.

23. Hirano S, Kondo S, Tanaka E, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat, 2010;17:455-62.

24. Tae Yoo, Sang-Jae Park, Sung-Sik Han, et al. Proximal Resection Margins: More Prognostic than Distal Resection Margins in Patients Undergoing Hilar Cholangiocarcinoma Resection. Cancer Res Treat. 2018;50(4):1106-1113.

25. Volkan Öter, İlter Özer, Tahsin Dalgıç, et al. Results of positive proximal margin after resection for hilar cholangiocarcinoma: An analysis of 42 cases. Turk J Gastroenterol 2019; 30(1): 88-94.

26. Hai-Jie Hu, Yan-Wen Jin, Anuj Shrestha, et al. Predictive factors of early recurrence after R0 resection of hilar cholangiocarcinoma: A single institution experience in China. Cancer Medicine. 2019;8:1567–1575.

27. Yunfeng Gao, Dong Xu, Yu-Shen Wu, et al. Increasing negative lymph node count is independently associated with improved long-term survival in resectable perihilar Cholangiocarcinomas. Medicine, 2019; 98:15.
# Tables

**Table 1. Clinicopathological characteristics of the enrolled 85 patients.**

| Program                  | Group     | Patients | Percentage |
|--------------------------|-----------|----------|------------|
| Gender                   | Male      | 56       | 65.9       |
|                          | Female    | 29       | 34.1       |
| Age                      | <64 years | 44       | 51.8       |
|                          | ≥64 years | 41       | 48.2       |
| ASA grade                | 0         | 0        | 0          |
|                          | 1         | 69       | 81.2       |
|                          | 2         | 16       | 18.8       |
| Height                   | <167cm    | 38       | 44.7       |
|                          | ≥167cm    | 47       | 55.3       |
| Weight                   | <60kg     | 23       | 41.2       |
|                          | ≥60kg     | 62       | 58.8       |
| BMI                      | Low       | 6        | 7.1        |
|                          | Normal    | 52       | 61.2       |
|                          | High      | 27       | 32.7       |
| TBIL \(\mu\text{mol/L}\) | 3.4-20.5  | 5        | 5.9        |
|                          | >20.5     | 80       | 94.1       |
| ALP \(\mu\text{U/L}\)   | 40-150    | 4        | 4.7        |
|                          | >150      | 81       | 95.3       |
| ALT \(\mu\text{U/L}\)   | 0-40      | 8        | 9.4        |
|                          | >40       | 77       | 90.6       |
| AST \(\mu\text{U/L}\)   | 5-34      | 8        | 9.4        |
|                          | >34       | 77       | 90.6       |
| ALB \(\text{g/L}\)      | 35-53     | 65       | 76.5       |
|                          | <35       | 20       | 23.5       |
| CA19-9 \(\text{U/ml}\)  | 0-37      | 10       | 11.8       |
|                          | 38-1000   | 64       | 75.3       |
|                          | >1000     | 11       | 12.9       |
| Imaging staging          | NA        | 2        | 2.3        |
|                          | Type I    | 13       | 15.3       |
|                          | Type II   | 29       | 34.1       |
|                          | Type IIIa | 8        | 9.4        |
|                          | Type IIIb | 10       | 11.8       |
|                          | Type IV   | 23       | 27.1       |
| Caudate lobe             | Yes       | 21       | 24.7       |
|                          | No        | 64       | 75.3       |
| Surgical time            | <300min   | 38       | 44.7       |
|                          | ≥300min   | 47       | 55.3       |
| Biliary plastic          | Yes       | 25       | 29.4       |
|                          | No        | 60       | 70.6       |

Table 1. Continued
|                          | Value 1 | Value 2 |
|--------------------------|---------|---------|
| Intraoperative blood loss| <500ml  | 63      | 74.1    |
|                         | ≥500ml  | 22      | 25.9    |
| Blood transfusion       | Yes     | 50      | 58.8    |
|                         | No      | 35      | 41.2    |
| Tumor size              | <3cm    | 49      | 57.6    |
|                         | ≥3cm    | 36      | 42.4    |
| Lymphatic metastasis    | Yes     | 20      | 23.5    |
|                         | No      | 65      | 76.5    |
| Resection margin        | Positive| 16      | 18.8    |
|                         | Negtive | 69      | 81.2    |
| TNM staging             | 0       | 0       | 0       |
|                         | I       | 23      | 27.1    |
|                         | II      | 31      | 36.5    |
|                         | III     | 26      | 30.6    |
|                         | 5       | 5.8     |         |

**Table2.** Cox single factor analysis for cholangiocarcinoma clinical data and treatment characteristics.
| Factor                                      | b    | SE(b) | Wald | df | p value | Hazard Ratio (HR) | 95% C for HR |
|---------------------------------------------|------|-------|------|----|---------|------------------|-------------|
| Gender                                      | -0.075 | 0.315 | 0.057 | 1  | 0.811   | 0.928 0.50     | 1.71        |
| Age                                         | -0.055 | 0.296 | 0.034 | 1  | 0.854   | 0.947 0.53     | 1.69        |
| Height                                      | -0.089 | 0.298 | 0.089 | 1  | 0.766   | 0.915 0.51     | 1.64        |
| Weight                                      | 0.302  | 0.372 | 0.658 | 1  | 0.417   | 1.353 0.65     | 2.80        |
| BMI                                         | -0.145 | 0.257 | 0.315 | 1  | 0.574   | 0.865 0.52     | 1.43        |
| ALT                                         | -0.012 | 0.527 | 0.001 | 1  | 0.982   | 0.988 0.35     | 2.77        |
| AST                                         | -0.250 | 0.528 | 0.225 | 1  | 0.635   | 0.779 0.27     | 2.19        |
| ALB                                         | 0.114  | 0.359 | 0.102 | 1  | 0.750   | 1.121 0.55     | 2.26        |
| Excise caudate lobe or not                  | -0.077 | 0.347 | 0.049 | 1  | 0.825   | 0.926 0.46     | 1.82        |
| Operation time                              | 0.034  | 0.297 | 0.013 | 1  | 0.910   | 1.034 0.57     | 1.85        |
| Bile duct plastic or not                    | -0.338 | 0.303 | 1.245 | 1  | 0.264   | 0.713 0.39     | 1.29        |
| Blood transfusion                           | 0.149  | 0.301 | 0.247 | 1  | 0.619   | 1.161 0.64     | 2.09        |
| CA199                                       | 1.058  | 0.324 | 10.686 | 1 | 0.001   | 2.880 1.52     | 5.42        |
| Lymphatic metastasis                        | -0.835 | 0.312 | 7.159 | 1  | 0.007   | 0.434 0.23     | 0.80        |
| ASA grade                                   | 0.465  | 0.364 | 1.629 | 1  | 0.202   | 1.592 0.78     | 3.25        |
| TBIL                                        | 0.601  | 0.321 | 3.511 | 1  | 0.061   | 1.823 0.97     | 3.41        |
| ALP                                         | -0.581 | 0.602 | 0.933 | 1  | 0.334   | 0.559 0.17     | 1.81        |
| Imaging staging                             | 0.236  | 0.099 | 5.686 | 1  | 0.017   | 1.266 1.04     | 1.53        |
| Intraoperative blood loss                   | 0.876  | 0.330 | 7.054 | 1  | 0.008   | 2.401 1.25     | 4.58        |
| Tumor size                                  | 1.096  | 0.302 | 13.121| 1  | 0.000   | 2.991 1.65     | 5.41        |
| TNM staging                                 | 0.691  | 0.186 | 13.796| 1  | 0.000   | 1.997 1.38     | 2.87        |
| Resection margin                            | -1.825 | 0.366 | 24.848| 1  | 0.000   | 0.161 0.07     | 0.07        |
Table 3. Multivariable regression analysis of HC using Cox proportional hazard model.

| Factor               | b    | SE(b) | Wald  | df | P value | Hazard Ratio (HR) | 95% CI for HR |
|----------------------|------|-------|-------|----|---------|-------------------|---------------|
| CA19-9               | 0.956| 0.347 | 7.605 | 1  | 0.006   | 2.602             | 1.319-5.135   |
| TNM staging          | 0.584| 0.180 | 10.555| 1  | 0.001   | 1.794             | 1.261-2.552   |
| Resection margin     | -1.487| 0.373 | 15.917| 1  | 0.000   | 0.226             | 0.109-0.469   |

Table 4. Comprehensive test of model coefficients d

| steps | -2ln(L) | Overall (score) | Change from the previous step |
|-------|---------|-----------------|-------------------------------|
|       |         | Wald df Sig.    |      Wald df Sig.             |
| 1 a   | 306.574 | 16.637 1 0.000 | 7.642 1 0.006                |
| 2 b   | 294.145 | 27.760 2 0.000 | 12.430 1 0.000               |
| 3 c   | 289.190 | 32.065 3 0.000 | 4.955 1 0.026               |

a: Input variables resection margin in step 1,

b: Input variables TNM staging in step 2,

c: Input variables CA19-9 in step 3,

d: Test method: step forward (likelihood ratio).